Amgen Inc

20 oct. 2026, 22:51 UTC

AstraZeneca and Amgen report full Phase III CROSSING trial results, showing TEZSPIRE® achieved significant improvements in eosinophilic esophagitis patients.

19 oct. 2026, 20:07 UTC

Amgen's stock declines as former CFO Peter Griffith announces move to Mattel, raising concerns about continuity in financial leadership.

16 oct. 2026, 20:07 UTC

Amgen Inc shares fell, reflecting a modest decline since Thursday's close, after earlier gains peaked around midday before pulling back.

15 oct. 2026, 20:01 UTC

Amgen Inc shares are advancing, supported by strength in the healthcare sector, while the XLV ETF also rises after reaching a record high.

14 oct. 2026, 23:41 UTC

Amgen Inc shares advanced in after-market trading, recovering from an initial dip and positioning above their 20-day moving average.

13 oct. 2026, 23:06 UTC

Amgen Inc shares declined modestly in after-market trading following a volatile session, though they remain above their 20-day moving average.

9 oct. 2026, 20:07 UTC

UBS analyst Michael Yee raised the price target on Amgen Inc to $470.00 from $430.00 while maintaining a Buy rating.

8 oct. 2026, 23:01 UTC

Amgen Inc shares are trading modestly higher in after-market hours, remaining above their 20-day moving average amid rising oil prices and inflation concerns.

7 oct. 2026, 23:11 UTC

Amgen Inc's shares declined slightly during after-market hours on Wednesday, following initial gains and positioning just below the regular session opening level.

6 oct. 2026, 23:15 UTC

Amgen Inc is trading modestly lower in after-market hours following a slight recovery earlier in the session, remaining in the middle of its one-month trading range.

2 oct. 2026, 20:07 UTC

Amgen Inc shares fell, continuing a downward trend with a cumulative drop since Thursday's close amid broader market declines.

1 oct. 2026, 23:05 UTC

Amgen Inc. is trading higher in after-market hours, despite a notable drop from an early high and marking its fourth consecutive session of lower closes.

30 sept. 2026, 23:40 UTC

Amgen Inc is trading modestly higher in after-market hours, supported by broader market gains and positive U.S. GDP and private sector job growth data.

29 sept. 2026, 20:07 UTC

Scotiabank raised Amgen's price target to $500 from $450, contributing to the stock's gains amid positive trial results for dazodalibep in systemic Sjögren's disease.

28 sept. 2026, 23:26 UTC

Amgen Inc's shares declined in after-market hours following the FDA's approval of Teva's Degevma, a biosimilar to Amgen's Xgeva, impacting its market position.

24 sept. 2026, 19:56 UTC

Amgen Inc shares are higher following positive topline results from its Phase 3 OASIZ 301 trial for dazodalibep in treating systemic Sjögren's disease.

23 sept. 2026, 23:41 UTC

Amgen Inc's shares are modestly higher in after-market trading, positioned near the midpoint of their one-month trading range.

22 sept. 2026, 20:01 UTC

Amgen shares advanced as the company reported positive topline results from its Phase 3 OASIZ 301 study for Sjögren's disease, achieving its primary endpoint.

21 sept. 2026, 20:06 UTC

Amgen Inc is advancing today, continuing its upward trajectory since Friday's close, despite remaining below its 20-day moving average.

18 sept. 2026, 20:06 UTC

Amgen Inc is trading higher on Friday, having advanced since Thursday's close, despite pulling back from an earlier session peak.

17 sept. 2026, 19:46 UTC

Amgen Inc is trading modestly higher, despite earlier fluctuations and remaining below its 20-day moving average amid a decline in U.S. jobless claims.

16 sept. 2026, 20:10 UTC

Amgen Inc has expanded its partnership with Veeva Systems, selecting Veeva Vault CRM to enhance global commercial execution, as shares trade slightly higher.

15 sept. 2026, 23:01 UTC

Amgen Inc shares are higher in after-market trading, reflecting a recovery from earlier losses despite being below its 20-day moving average and one-month range.

14 sept. 2026, 20:08 UTC

Amgen Inc. shares rise after FDA approval for IMDELLTRA, reducing monitoring time for patients with extensive-stage small cell lung cancer. Positive sentiment noted on social media.

11 sept. 2026, 20:08 UTC

Amgen Inc shares are lower today following a drop in the Michigan Consumer Sentiment index, raising concerns over inflation and household budgets.

10 sept. 2026, 23:41 UTC

Amgen Inc. shares are higher in after-market trading, continuing a modest advance since Thursday's close, despite four consecutive lower daily closes.

8 sept. 2026, 20:03 UTC

Amgen Inc shares are lower today following Novartis' trial failure and a downgrade by BMO Capital to Market Perform, amid significant sell-off pressure.

4 sept. 2026, 23:02 UTC

Amgen Inc shares are lower in after-market hours, reflecting ongoing weakness. The stock is trading below its 20-day moving average and near a one-month low.

3 sept. 2026, 20:08 UTC

Erste Group Bank raised Amgen's FY2027 EPS estimate to $24.43, surpassing consensus. Shares are higher, continuing a trend of gains this week.

2 sept. 2026, 23:01 UTC

Amgen Inc. shares are lower in after-market hours despite announcing participation in the 2026 Wells Fargo Healthcare Conference on September 10, 2026.